RxDoctor Payments Data

Yunior Martinez Duenas, MD

Family Medicine · Bakersfield, CANPI 1659804748

Payments from drug & device makers

$1,635in general payments, 2019–2025

Across 101 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$383
  • Novo Nordisk$363
  • Viiv Healthcare Company$155
  • GSK$145
  • Lilly USA, LLC$112
  • Exact Sciences$81
  • plus $396 from 12 others

What the payments were for

  • Food & beverage$1,47490%
  • Education$16110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,635 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$369
Medicare patients
35
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin113$168,803
OzempicSemaglutide52$68,063
FarxigaDapagliflozin Propanediol58$52,033
RybelsusSemaglutide36$44,702
EliquisApixaban38$35,105
JanuviaSitagliptin Phosphate25$33,325
TradjentaLinagliptin31$32,938
Tresiba Flextouch U-100Insulin Degludec15$7,293
Combivent RespimatIpratropium/Albuterol Sulfate11$5,446
Atorvastatin Calcium584$4,830
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,708
LumiganBimatoprost14$3,802
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$2,853
VascepaIcosapent Ethyl13$2,594
Albuterol Sulfate HfaAlbuterol Sulfate77$2,242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$59$207,187155 claims
Novo NordiskOzempic, Rybelsus$363$112,76588 claims
AstraZenecaFarxiga$27$52,03358 claims
PfizerEliquis$27$35,10538 claims
MerckJanuvia$49$33,32525 claims
AbbVieLumigan$21$3,80214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →